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doi:10.1Objective: We evaluated roles of serotonin 1B and 2A receptors, thromboxane synthase and receptor, and phos-
pholipases A2 and C in response to cardiopulmonary bypass.
Methods: Patients’ atrial tissues were harvested before and after cardiopulmonary bypass with cardioplegia (n¼
13). Coronary microvessels were assessed for vasoactive response to serotonin with and without inhibitors of
serotonin 1B and 2A receptors and phospholipases A2 and C. Expressions of serotonin receptor messenger
RNA were determined with reverse transcriptase polymerase chain reaction. Expressions of serotonin receptors
and thromboxane A2 receptor and synthase proteins were determined with immunoblotting and immunohisto-
chemistry.
Results: Microvessel exposure to serotonin elicited 7.3%  2% relaxation before bypass, changing to contrac-
tion of19.2% 2% after bypass (P<.001). Additions of specific serotonin 1B receptor antagonist and inhibitor
of phospholipase A2 resulted in significantly decreased contraction,8.6%  1% (P< .001) and 2.8%  3%
(P ¼ .001), respectively. Serotonin 1B receptor messenger RNA expression increased 1.82  0.34-fold after
bypass (p ¼ .044); serotonin 2A receptor messenger RNA expression did not change. Serotonin 1B but not
2A receptor protein expression increased after bypass by 1.35  0.7-fold (P ¼ .0413). Thromboxane synthase
and receptor expressions were unchanged after bypass. Serotonin 1B receptor increased mainly in arterial smooth
muscle. There were no appreciable differences in arterial expressions of thromboxane synthase or receptor.
Conclusions: Serotonin-induced vascular dysfunction after cardiopulmonary bypass with cardioplegic arrest
may be mediated by increased expression of serotonin 1B receptor and subsequent phospholipase A2 activation
in myocardial coronary smooth muscle. (J Thorac Cardiovasc Surg 2010;139:1033-40)E
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SEndothelial dysfunction occurs in many cardiovascular dis-
eases, including hypertension, diabetes mellitus, hyperlipid-
emia, and atherosclerosis.1-3 It is also estimated to occur in
a clinically relevant manner in as many as 2.5% of patients
after cardiac surgery,4 with electrocardiographic changes oc-
curring in as many as 8% of patients.5 These clinical events
are thought to be secondary to altered vasomotor regulation
caused by coronary artery and microvascular spasm. This al-
tered response has been implicated as a cause of myocardial
ischemia in a number of clinical situations, such as angina,
acute coronary syndrome, and vasospasm after coronary ar-
tery bypass grafting with cardioplegic cardiopulmonary by-
pass (CP-CPB). A number of vasoactive substances havee Department of Surgery,a Division of Cardiothoracic Surgery, Beth Israel
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The Journal of Thoracic and Carbeen implicated in this process. These include thrombin,5 en-
dothelin,6 adenosine diphosphate, thromboxane A2 (TXA2),
7
acetylcholine,8 nitric oxide,9 adenosine,10 reactive oxygen
species (which interfere with endothelium-dependent relaxa-
tion),11 and serotonin.12
Serotonin is a vasoreactive amine with numerous actions
affecting the circulation of various organs, and its actions
are mediated by multiple receptor subtypes. There are two
major serotonin receptor subtypes expressed in heart tissue,
5-HT1B and 5-HT2A, which can have opposing effects on
the coronary vasculature. The 5-HT2A receptor often acts
as a vasodilator, whereas 5-HT1B acts as a vasoconstric-
tor.13-15 In a recent study, Shimizu and colleagues16 infused
the 5-HT1B agonist sumatriptan into the coronary arteries
of 9 patients, 5 with confirmed variant angina. Sumatriptan
elicited coronary artery spasm in all patients with variant
angina. Similarly, Dahlof and Mathew17 reviewed the liter-
ature on reports of cardiovascular complications of patients
taking sumatriptan for treatment of migraines. They noted
that 3% to 5% of patients reported chest tightness or pres-
sure after taking the drug. Although no electrocardiographic
or echocardiographic data supported this sensation as being
of cardiac origin, they considered the anecdotal data suffi-
cient to recommend caution in using 5-HT1 agonists in pa-
tients at high risk for coronary artery disease or
vasospasm. In previous studies, we have shown thatdiovascular Surgery c Volume 139, Number 4 1033












5-HT1B ¼ serotonin (5-hydroxytryptamine)
receptor type 1B
5-HT2A ¼ serotonin (5-hydroxytryptamine)
receptor type 2A
CP-CPB ¼ cardioplegic cardiopulmonary bypass
mRNA ¼ messenger RNA
PLA2 ¼ phospholipase A2
TR ¼ thromboxane receptor
TS ¼ thromboxane synthase
TXA2 ¼ thromboxane A2myocardial dysfunction after CP-CPB is associated with in-
creased coronary contraction mediated by serotonin18 and
with a switch from serotonin-induced coronary vasodilation
before CP-CPB to contraction after CP-CPB.
Serotonin has been shown to activate phospholipase A2
(PLA2), which is known to release arachidonic acid, theURE 1. Coronary microvascular response to serotonin in vitro. A, Diame
ups in baseline vessel diameter (p ¼ .4). B, Diameter of microvessels after
log. There were no differences among groups before addition of serotonin (p
ass with cardioplegic arrest (Pre-CP-CPB) with and without selective seroto
tonin to microvessels harvested before cardiopulmonary bypass with card
-CPB, Before cardiopulmonary bypass; Post-CPB, after cardiopulmonary by
receptor blocker SB224289.
34 The Journal of Thoracic and Cardiovascular Surprecursor to a number of inflammatory mediators including
TXA2.
19 Activation of PLA2, by serotonin receptors or other
receptors, may contribute to vasoconstriction after CP-CPB.
Our hypothesis is that the differential response to serotonin
may be caused by a shift in the proportions of receptor sub-
types expressed.
Thromboxane synthase (TS) and the thromboxane recep-
tor (TR) have also been implicated in leading to vasocon-
striction after CP-CPB, and in conjunction with serotonin
may lead to further exacerbation of the vessel contraction.
It is clear this is a complex and multifactorial process, and
this study was designed specifically to examine changes in-
duced in the serotonin receptor subtypes, TS, TR, phospho-
lipase C (PLC), and PLA2 by CP-CPB, because these may
contribute to a vasoconstrictive local milieu after CP-CPB.
MATERIALS AND METHODS
Collection of Tissues
Right atrial tissues were harvested from patients undergoing coronary
artery bypass grafting with CP-CPB. Aspirin was discontinued 24 hours
before surgery, but other medications were continued up to the time ofter of microvessels before precontraction. There was no difference among
precontraction. Vessels were precontracted with U46619, thromboxane A2
¼ .31). C, Serotonin responses of vessels harvested before cardiopulmonary
nin 1B receptor blocker (SB224289). Blocker administered in presence of
ioplegic arrest resulted in response similar to serotonin alone (P ¼ .44).
pass; Post-CPBþSB224289, after cardiopulmonary bypass with serotonin
gery c April 2010
Robich et al Evolving Technology/Basic Scienceoperation. Double cannulation sutures were placed in the atrial appendage.
The first excised portion of right atrial tissue was harvested after hepariniza-
tion but before initiation of CP-CPB (before group). The second portion of
atrium was harvested after crossclamp removal and termination of CP-CPB
but before protamine administration (after group). Cold blood cardioplegia
solution was used. Tissues in the before and after groups were immediately
frozen in liquid nitrogen after harvest in preparation for molecular studies,
placed in cold (5C–10C) Krebs buffer solution for vascular reactivity
studies, or fixed in 10% formalin overnight and embedded in paraffin for
immunohistochemical studies.
The study was approved by the clinical research committee of Beth Israel
Deaconess Medical Center. Informed consent was obtained from each patient.In Vitro Atrial Microvascular Studies
Coronary microvascular reactivity was examined in the ischemic terri-
tory as previously described.20 Briefly, coronary arterioles (70–180 mm)
were dissected with a 403 microscope. Microvessels were mounted on
dual glass micropipettes and examined in a pressurized, isolated microves-
sel chamber. Relaxation responses of microvessels were examined after
development of spontaneous tone with supplemental precontraction by
the TXA2 analog U46619. Vascular responses to serotonin (10
9–104
mol/L) alone and in the presence of a specific 5-HT1B receptor antagonist,
SB224289 (106 mol/L), before and after CP-CPB were examined. Vessel
responses to inhibitors of PLA2 (quinacrine, 10
6 mol/L) and PLC
(U73122, 106 mol/L) before and after CP-CPB were also examined. All
reagents were from Sigma-Aldrich (St Louis, Mo).FIGURE 2. Serotonin-induced coronary microvascular response to serotonin rec
phospholipase A2 inhibitor (U73122) in vitro. A, Coronary microvascular respon
pulmonary bypass (Pre CP-CPB).After bypass (Post CP-CPB),microvessels sw
blocker SB224289, postbypass contraction response was significantly diminishe
indicates difference after bypass with and without antagonist P<.001. B, Microv
acrine and phospholipase A2 inhibitor U73122 before cardioplegic cardiopulmon
P ¼ .38). After cardioplegic cardiopulmonary bypass, microvessels subjected to
response with serotonin alone (asterisk indicates P< .001). Contractile respons
with cardioplegic arrest was not significantly different from serotonin alone (P
The Journal of Thoracic and CarExpressions of 5-HT1B and 5-HT2AMessenger RNA
For 5HT-1B and 5HT-2A messenger RNA (mRNA) studies, semiquan-
titative reverse transcriptase–polymerase chain reaction was performed.
Primers were designed on the basis of published sequences.14 The 5-
HT1A primers of the sense 50-ACAGAATTCATGGATGTGCTCA
GCCCTGGTCA-30and the antisense 50-TCTGTCGACTCACTGGCGG
CAGAAGTTACACTTAAT-30 were used. For 5-HT2A, the primer of
sense 50-GCGGGTACCATGCAATTAAATGATGACACCAGGCTC-30
and the antisense 50-TATCTCGAGTCCACAGTTGCCACGGCAACTA-
30 were used. Equal amounts of total RNA were used. For quantification,
glyceraldehyde-3-phosphate dehydrogenase was amplified from the same
amount of RNA to correct for variation of different samples. The polymer-
ase chain reaction products were loaded in a 1% agarose gel containing
ethidium bromide and scanned and quantified with Image-Quant software
(Molecular Dynamics, Sunnyvale, Calif).
Expressions of 5-HT1B, 5-HT2A, TS, and TR
Proteins
Myocardial samples were homogenized in radioimmunoprecipitation
assay buffer (Boston Bioproducts, Worcester, Mass) and protein concentra-
tion determined by BCA assay (Thermo Fisher Scientific Inc, Waltham,
Mass). Total protein (40 mg/lane) was fractionated by 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred to a polyvinyli-
dene difluoride membrane (Immobilon-P; Millipore, Bedford, Mass). Equal
protein loading was determined by Ponceau staining. The membranes were
incubated with either anti–5-HT1B at 1:100 (vol/vol) dilution (BDeptor 1B inhibitor (SB224289), phospholipase C inhibitor (quinacrine), and
se to serotonin demonstrates relaxation response before cardioplegic cardio-
itched to strong contraction response. After addition of serotonin 1B receptor
d. Asterisk indicates difference before and after bypass P< .001; plus sign
ascular response to serotonin in presence of phospholipase C inhibitor quin-
ary bypass (quinacrine to serotonin alone P¼ .17, U73122 to serotonin alone
quinacrine yielded significant reduction in contractile response relative to
e when U73122 was applied to microvessels after cardiopulmonary bypass
¼ .58).









SBiosciences, San Jose, Calif), anti–5-HT2A at 1:100 dilution (BD Biosci-
ences), anti–TXA2 synthase at 1:300 dilution (Santa Cruz Biotechnology,
Inc, Santa Cruz, Calif), or anti–TXA2 receptor at 1:100 (Santa Cruz Biotech-
nology, Inc). After washing, the membranes were incubated in appropriate
secondary antibody. Peroxidase activity was visualized with an enhanced
chemiluminescence substrate system (Amersham, Fairfield, Conn) and ex-
posure to x-ray film. Densitometry of digitized x-ray films (ScanJet 4c;
Hewlett-Packard Company, Palo Alto, Calif) was performed with Image-
Quant software (Molecular Dynamics Inc, Sunnyvale, Calif). Data are pre-
sented as mean  SEM in arbitrary density units.
Immunohistochemical Studies
Formalin-fixed tissue samples were deparaffinized, rehydrated, and incu-
bated with 3% hydrogen peroxide. Antibodies against 5-HT1B or 5-HT2A
(2 mg/mL; BD Biosciences) were applied to the sections, and isotype-
matched control antibody (negative control) was applied in the same dilu-
tion for 2 hours at room temperature. After a wash in phosphate-buffered
saline solution, immunoreactivity was detected with a biotinylated goat
anti–mouse secondary antibody and the avidin-biotin-peroxidase complex
(Vector Laboratories, Burlingame, Calif). Color was developed with diami-
nobenzidine substrate (1 mg/mL in phosphate buffered saline solution and
0.03% hydrogen peroxide). Sections were then counterstained with hema-
toxylin, dehydrated, and mounted. Photomicrographs were taken with
a Zeiss Axiolab microscope (Carl Zeiss Inc, Thornwood, NY) equipped
with digital camera (Photodoc, Upland, Calif).
Statistics
Microvascular reactivity data were analyzed with 2-way repeated mea-
sures analysis of variance. Densitometry data were analyzed with 1 way
analysis of variance (Systat, San Jose, Calif). Data are reported as mean
 SEM.RESULTS
Atrial was obtained from 13 patients. All were male, with
an average age of 66.8  4 years. Seventy-seven percent of
the patients had hypertension, 54% had hyperlipidemia, and
23% had diabetes mellitus. Four were smokers at the time of
operation. The average preoperative ejection fraction was
46.4%  5.8%. Mean cardioplegia time was 58  7 min-
utes, and the mean time from crossclamp removal until sec-
ond tissue harvest was 10  3 minutes. None of the patients
in this study had any major clinical adverse events, including
overt evidence of myocardial ischemia, unexpected hemo-
dynamic instability, or cardiac depression.FIGURE 3. Serotonin 1B receptor messenger RNA expression by reverse
transcriptase–polymerase chain reaction A, Expression of serotonin 1B re-
ceptor messenger RNA was increased (asterisk indicatesP¼ .044) after car-
diopulmonary bypass (Post-CPB) versus before cardiopulmonary bypass
(Pre-CPB). B, Agarose–ethidium bromide gel (1%) showing polymerase
chain reaction amplification of serotonin 1B receptor (5HT-1B) after cardio-
pulmonary bypass (Post) versus before cardiopulmonary bypass (Pre), nor-
malized to 1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as loading control. Data presented as fold change  SEM. BP, Base
pairs.Microvessel Characteristics
Atrial microvessel internal diameter ranged from 70 to
180 mm, averaging 106  4 mm before CP-CPB and 123
 13 mm after CP-CPB (Figure 1, A and B). The vessels be-
fore CP-CPB demonstrated a relaxation response that was
not affected by the presence of the 5-HT1B receptor antag-
onist SB224289 (Figure 1, C). After CP-CPB, vessels dem-
onstrated a strong contraction response. This contraction
response was diminished in the presence of SB224289
(Figure 2, A). Addition of quinacrine, a selective PLA2 in-
hibitor, had no effect on the microvessels before CP-CPB
but significantly inhibited the contraction response after1036 The Journal of Thoracic and Cardiovascular SurCP-CPB. Addition of the PLC inhibitor resulted in no
change in the contraction response (Figure 2, B).
Serotonin Receptor, TS, and TR Expressions
Expressions of 5-HT1B and 5-HT2A receptors were ana-
lyzed by semiquantitative reverse transcriptase–polymerase
chain reaction. The 5-HT1B receptor mRNA expression
increased an average of 1.82  0.34-fold after CP-CPB
(Figure 3, A and B), whereas the 5-HT2A receptor mRNA
expression was unchanged (P ¼ .509; not shown).
Western blotting showed that 5-HT1B protein expres-
sion was increased 1.35  0.7-fold after CP-CPB (Figure 4,
A and B), whereas 5-HT2A receptor did not change (P ¼
.951; not shown). Likewise, TR and TS protein levels
were unchanged (Figure 4, A, C, and D).
Immunohistochemical Studies
Immunohistochemical examination demonstrated increased
5-HT1B expression after CP-CPB, whereas 5-HT2A appearedgery c April 2010
FIGURE 4. Serotonin 1B receptor, thromboxane receptor, and thromboxane synthase protein expressions by western blotting. A, Expression of serotonin 1B
receptor protein (5-HT1B) was found to increase after cardiopulmonary bypass (post) relative to before cardiopulmonary bypass (pre). Expressions of throm-
boxane receptor and thromboxane synthase were not significantly changed in myocardial tissue. Ponceau stain is used for loading and transfer monitoring.
B, Serotonin 1B receptor protein expression after cardiopulmonary bypass (Post-CPB) versus before cardiopulmonary bypass (Pre-CPB) normalized to 1
(asterisk indicates P ¼ .041). C, Thromboxane receptor protein expression after cardiopulmonary bypass (Post-CPB) versus before cardiopulmonary bypass
(Pre-CPB) normalized to 1 (asterisk indicates P¼.62). D, Thromboxane synthase protein expression after cardiopulmonary bypass (Post-CPB) versus before
cardiopulmonary bypass (Pre-CPB) normalized to 1 (asterisk indicates P ¼.18). Data presented as fold change  SEM.




Sunchanged (Figure 5,A andB), particularly in coronary vessels.
The 5-HT1B expression was increased in the arterial media
smooth muscle. There were no apparent changes in TR
(Figure 5, C) or TS (not shown).
DISCUSSION
In this study, we examined coronary microvascular re-
sponses before and after CP-CPB. Atrial microvessels
harvested before CP-CPB displayed a small relaxation re-
sponse to serotonin. In contrast, the coronary vessels
isolated after CP-CPB displayed a strong contractileThe Journal of Thoracic and Carresponse to serotonin. These findings indicate changes
in the vasomotor pathways after surgery, with a possible
shift in receptor subtype expression accounting for this
functional change. The addition of 5-HT1B blocker sig-
nificantly diminished the contractile response, suggesting
the vasoconstriction after CP-CPB is at least in part medi-
ated by 5-HT1B. Addition of a PLA2 inhibitor also signif-
icantly attenuated the contractile response to serotonin
after CP-CPB, but a PLC inhibitor was ineffective. There
were no significant differences in the tissue expressions of
TR and TS.diovascular Surgery c Volume 139, Number 4 1037
FIGURE 5. Localization of serotonin 1B (5-HT1B) and serotonin 2A (5-HT2A) receptors and thromboxane receptor by immunohistochemistry and immu-
nofluorescence, respectively. A, Expression of serotonin 1B receptor is upregulated in vascular smooth muscle cells. B, Expression of serotonin 2A receptor is
unchanged after cardiopulmonary bypass. C, Expression of thromboxane receptor is unchanged between before and after bypass. Original magnification for
immunohistochemistry 4003; original magnification for immunofluorescence 2003. Large open arrow indicates vascular smooth muscle cells; small black
arrow indicates endothelium. Pre-CPB, Before cardiopulmonary bypass; Post-CPB, after cardiopulmonary bypass.




SCoronary microcirculation provides significant control of
myocardial perfusion.21 It has been shown that the micro-
vascular response to neurohumoral substances, such as sero-
tonin and norepinephrine, is often different in magnitude or
opposite to that observed in large vessels.22,23 Thus, the
study of microvascular regulation is likely more physiolog-
ically relevant than alterations in larger vessels.
To explore further the possibility of altered serotonin
receptor expression, we examined the transcriptional and
translational products of the two most commonly implicated
receptor subtypes.24 We demonstrated upregulation of 5-
HT1B receptor mRNA and protein expressions by reverse
transcriptase–polymerase chain reaction and western blot-
ting. Both 5-HT2A expressions were unchanged. These
findings support the concept of a shift in serotonin receptor
subtypes in response to CP-CPB, with 5-HT1B contributing
to the change in microvascular response.
An upregulation of the 5-HT1B receptor occurred after
surgery. Changes in 5-HT1B receptor expression have
been demonstrated in other studies in a similarly brief1038 The Journal of Thoracic and Cardiovascular Surperiod. In a study of the cerebral vasculature during ischemia
and reperfusion, it was noted that 5-HT1B receptor expres-
sion was upregulated in the vascular smooth muscle cells
within 60 minutes of the onset of ischemia.25 It was hypoth-
esized the expression was controlled by MEK1 activating
Erk1 and Erk2, which in turn activated the transcription
factor Elk1. In that study, administration of a MEK1 inhib-
itor diminished the upregulation of 5-HT1B receptor.
The dual endothelin 1 receptor antagonist bosentan, used
in the treatment of pulmonary hypertension, has also been
shown to partially inhibit 5-HT1B receptors and thus may
have a role in treatment of vasoconstriction after CP-CPB
through antagonist effects on serotonin receptors as well
as endothelin.6,26
Coronary vasoconstriction has been implicated in myo-
cardial ischemia in a number of clinical situations, including
stable and variant angina, acute coronary syndrome, and car-
diac surgery.27,28 Other studies have indicated that serotonin
may contribute to postischemic coronary vascular constric-
tion.8,11,13,14,18 It has been postulated that atherosclerosisgery c April 2010
FIGURE 6. Summary of serotonin (5-HT) receptor expression before (Pre CPB) and after (Post CPB) cardiopulmonary bypass. Expression of serotonin 1B
(5-HT1B) receptor is significantly increased after bypass and associated with vasoconstriction, whereas expression of serotonin 2A (5-HT2A) receptor is
unchanged after bypass. Serotonin, thromboxane A2 (TXA2), adenosine diphosphate (ADP), and other mediators are released from platelets. Platelets are
activated after bypass and degranulate, releasing many substances. Endothelium also produces serotonin. Serotonin 1B receptors are negatively coupled
to adenylyl cyclase (AC), and serotonin 2A receptors are positively coupled to phospholipase C (PLC). Serotonin activates phospholipase A2 (PLA2) and
may lead to further increases in thromboxane A2. All signals influence vascular smooth muscle cells (VSMC) to respond. AA, Arachidonic acid.




Smay cause a shift in serotonin receptor subtypes in vascular
smooth muscle cells by increased receptor-mediated calcium
ion mobilization.24 Serotonin receptor subtypes have vari-
ous, and at times opposing, effects on different vascular
beds in different species.7,13,29 Both 5-HT1B and 5-HT2A
are expressed on the vascular smooth muscle cells, but
they mediate their responses through different mechanisms.
The 5-HT1B receptors work through PLA2 and adenylyl
cyclase; in contrast 5-HT2A receptors are positively coupled
to PLC.29,30 Although our evidence strongly supports in-
creased PLA2-dependent 5-HT1B signaling, we can not
definitively rule out that changes in microvessel reactivity
might be due to alternative changes in second messengers
or other unaccounted for receptor subtypes.
TS and the TR have also been implicated in causing va-
soconstriction after CP-CPB. We have previously shown
that cyclooxygenase 2 expression is increased after cardiac
operations, and the presence of a cyclooxygenase 2 inhib-
itor or a TS inhibitor markedly diminishes the contractile
response to serotonin in this setting.12 From that study, it
appears that serotonin elicits the synthesis and release of
TXA2. This may be mediated by activation of PLA2, which
releases arachidonic acid and leads to production of, among
other products, TXA2.
31-33 In this study, we found no sig-
nificant differences in TS and TR expression, although ac-
tivity was not measured. The improvement by the PLA2The Journal of Thoracic and Carinhibitor in contraction after CP-CPB may be secondary
to production of less TXA2. Studies measuring levels of
TXA2 locally in the presence of a PLA2 inhibitor would
be needed to support this.
In addition, the roles of platelets and other circulating
cells in this process are not accounted for, and they have
been shown to be critical.34 It is possible that the primary
source of serotonin in the post–cardiac surgery setting
is from activated platelets. In a study characterizing the ex-
pression of TS, it was found to be most abundant in circulat-
ing cells, being present to a lesser degree in spleen, liver,
and lung, and essentially undetectable in heart tissue.35 Al-
though there did not appear to be any changes in TS and
TR expressions in the atrial microcirculation, circulating
blood components, mostly platelets, may be delivering
higher concentrations of thromboxane and serotonin to the
vessel and thus effecting a greater response.
In this study, we found an approximately 50% reduction
in the vasoconstrictive response with a specific 5-HT1B re-
ceptor blocker and 84% reduction with an inhibitor of the
second messenger PLA2, both of which should result in sig-
nificant hemodynamic improvement. This also indicates,
however, that there are other factors contributing to the
vasoconstriction. Studies are currently underway to charac-
terize other mediators of vasomotor dysfunction after CP-
CPB.diovascular Surgery c Volume 139, Number 4 1039





This study has shown the potential role in coronary vaso-
spasm after cardiac surgery of changes in serotonin receptor ex-
pression. A limitation of this study, however, is the relatively
small sample size. There were multiple and varying risk factors
in each patient, all of which could have had an impact on the
results. It is possible that there are differences depending on
the presence of diabetes, hypercholesterolemia, and other coex-
isting conditions, or certain medications may have effects.
Future studies with larger numbers of patients could be under-
taken to elucidate further how specific variables, such as co-
morbidities and medications (eg, b-blockers, amiodarone,
angiotensin-converting enzyme inhibitors, and insulin) con-
tribute to the observed process. Future studies will also further
examine the second messengers involved with the 5-HT1B
receptor, because these may be different before and after CP-
CPB, leading to the divergent vasomotor responses. In
addition, right atrial tissues were examined as a surrogate for
ventricular myocardium. We have already shown, however,
that human atrial myocardial microvessels responses are sim-
ilar to those observed in the ventricular microcirculation.
Clinical Implications
The contraction response demonstrated in this experiment
has been implicated as a cause of myocardial ischemia in
a number of clinical situations, such as angina, acute coro-
nary syndrome, and vasospasm after cardiac surgery. It is
clearly a complex and multifactorial process mediated by
a number of pathways. Antagonizing the increased vasocon-
strictive 5-HT1B receptor along with other components in
the signaling pathways may allow clinicians to alleviate
myocardial ischemia in the postsurgical setting.
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